FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies
Illumina(ILMN) Prnewswire·2024-08-27 21:15
"FDA approval for TruSight Oncology Comprehensive with accompanying companion diagnostics marks an awaited milestone for our oncology customers and community," said Everett Cunningham, chief commercial officer of Illumina. "We are committed to partnering with industry leaders like Bayer and Lilly to advance cancer diagnostics and help broaden access to precision oncology for more patients."A CDx test may identify whether a patient's tumor has a specific gene change or biomarker that can be targeted by a the ...